Exercise or conversion by T Washburn of 4150 shares of Agios Pharm subject to Rule 16b-3

AGIO Stock  USD 59.39  0.73  1.24%   
About 65% of all Agios Pharm's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Agios Pharm suggests that some traders are interested. Agios Pharm's investing sentiment overview a quick insight into current market opportunities from investing in Agios Pharm. Many technical investors use Agios Pharm stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Agios Pharmaceuticals Inc officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Read at macroaxis.com
Agios insider trading alert for exercise of common stock by T Washburn, Principal Accounting Officer, on 2nd of August 2023. This event was filed by Agios Pharmaceuticals Inc with SEC on 2023-08-02. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Agios Pharm's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Agios Pharm's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Agios Pharm Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Agios Pharm can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Agios Pharm Fundamental Analysis

We analyze Agios Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agios Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agios Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

Agios Pharm is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Agios Pharm Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Agios Pharm stock to make a market-neutral strategy. Peer analysis of Agios Pharm could also be used in its relative valuation, which is a method of valuing Agios Pharm by comparing valuation metrics with similar companies.

Peers

Agios Pharm Related Equities

CCCCC4 Therapeutics   8.59   
0%
100.0%
NRIXNurix Therapeutics   4.15   
0%
48.0%
MRSNMersana Therapeutics   4.11   
0%
47.0%
MGTXMeiraGTx Holdings   3.36   
0%
39.0%
BDTXBlack Diamond   3.11   
0%
36.0%
ARVNArvinas   2.85   
0%
33.0%
CGEMCullinan Oncology   2.75   
0%
32.0%
PLRXPliant Therapeutics   2.00   
0%
23.0%
STOKStoke Therapeutics   1.68   
0%
19.0%
DAWNDay One   1.53   
0%
17.0%
MREOMereo BioPharma   1.40   
0%
16.0%
IDYAIdeaya Biosciences   1.37   
0%
15.0%
BPMCBlueprint Medicines   1.35   
0%
15.0%
SNDXSyndax Pharmaceuticals   1.27   
0%
14.0%
BMRNBiomarin Pharmaceutical   0.93   
0%
10.0%
KYMRKymera Therapeutics   0.02   
1.0%
0%
KALVKalvista Pharmaceuticals   0.30   
3.0%
0%
ANABAnaptysBio   0.64   
7.0%
0%
COGTCogent Biosciences   0.73   
8.0%
0%
RVMDRevolution Medicines   1.25   
14.0%
0%
KROSKeros Therapeutics   1.38   
16.0%
0%
RLAYRelay Therapeutics   2.08   
24.0%
0%
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:
Check out Agios Pharm Hype Analysis, Agios Pharm Correlation and Agios Pharm Performance.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
11.66
Revenue Per Share
0.582
Quarterly Revenue Growth
0.212
Return On Assets
(0.18)
Return On Equity
0.5366
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.